BioAscent key facts
as of Oct 2026- Provider of integrated drug discovery services intended to reach key stages of the drug discovery process.
- BioAscent is valued at approximately $4.3M as of Oct 2026 (last reported valuation).
- It has raised $2.1M; the latest was Later Stage VC in Apr 2025.
- Notable investors include Maven Capital Partners UK, Pioneer Group.
- Status: Privately Held (backing).
BioAscent's last reported valuation, Jun 2018. Nothing priced has surfaced since.
- ·Watch BioAscent: the Monday email on marks, rounds and moves
BioAscent funding rounds
No funding rounds for BioAscent are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs BioAscent
2BioAscent valuation
BioAscent's last reported valuation was $4.3 million in Jun 2018. No priced round, secondary trade or fund mark has surfaced since.
BioAscent investors
2 investors are on record for BioAscent, including Maven Capital Partners UK and Pioneer Group.
About BioAscent
Provider of integrated drug discovery services intended to reach key stages of the drug discovery process. The company offers a range of services, including target analysis, bespoke screening strategies, compound screening, and data management, enabling pharmaceutical businesses to maximize their lead findings and increase the success rate of discovery projects at a lower cost.
- Sector
- Healthcare
- HQ
- Motherwell, United Kingdom
- Founded
- 2013
- Employees
- 77
- Website
- bioascent.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.